<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03829319</url>
  </required_header>
  <id_info>
    <org_study_id>7902-006</org_study_id>
    <secondary_id>2018-003824-35</secondary_id>
    <secondary_id>MK-7902-006</secondary_id>
    <secondary_id>E7080-G000-315</secondary_id>
    <secondary_id>LEAP-006</secondary_id>
    <secondary_id>194658</secondary_id>
    <nct_id>NCT03829319</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)</brief_title>
  <official_title>A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum
      chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as
      first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer.

      The primary study hypotheses state that: 1) the combination of lenvatinib + platinum doublet
      chemotherapy + pembrolizumab prolongs Progression-free Survival (PFS) as assessed by blinded
      independent central review (BICR) per modified Response Evaluation Criteria in Solid Tumors
      version 1.1 (RESIST 1.1) compared to matching placebo + platinum doublet chemotherapy +
      pembrolizumab, and 2) the combination of lenvatinib + platinum doublet chemotherapy +
      pembrolizumab prolongs Overall Survival (OS) compared to matching placebo + platinum doublet
      chemotherapy + pembrolizumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">June 21, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants with a Dose-limiting Toxicity</measure>
    <time_frame>Cycle 1; each cycle is 21 days (up to 21 days)</time_frame>
    <description>Dose-limiting toxicity using Common Terminology Criteria for Adverse Events v4.0 for grading, is defined as any of the following hematologic toxicities: 1) Grade 4 neutropenia, 2) Grade 3 or 4 febrile neutropenia, 3) thrombocytopenia &lt;25,000 cells/mm^3 associated with bleeding and/or which requires platelet transfusion, or any of the following non-hematologic toxicities: 4) any other Grade 4 or 5 toxicity, 5) Grade 3 toxicities lasting &gt;3 days (exclusions apply), 6) Grade 3 hypertension not controlled by medication, 7) Grade 3 or above gastrointestinal perforation, 8) Grade 3 or above wound dehiscence requiring medical or surgical intervention, 9) any grade thromboembolic event, or 10) any Grade 3 nonhematologic laboratory value if medical intervention is required or the abnormality leads to hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants with One or More Adverse Events</measure>
    <time_frame>Through 90 days post last dose of study treatment (Up to approximately 27 months)</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one of more adverse events during Part 1 of this study will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Progression-free Survival (PFS) as Assessed by BICR according to RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>PFS is defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. PFS as assessed per modified RECIST 1.1 will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Overall Survival (OS)</measure>
    <time_frame>Up to approximately 60 months</time_frame>
    <description>OS is defined as the time from randomization to the time of death from any cause. OS will be presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Objective Response Rate (ORR) as Assessed by BICR according to RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. ORR as assessed per modified RECIST 1.1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2; Duration of Response (DOR) as Assessed by BICR according to RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the time from the first documented evidence of CR or PR until PD or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or death from any cause, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. DOR as assessed per modified RECIST 1.1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants with One or More Adverse Events</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one of more adverse events during Part 2 of this study will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants Who Discontinue Study Treatment Due to an Adverse Event</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment during Part 2 of this study will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life; Cough; Chest Pain; Dyspnea; and Physical Functioning Combined Score</measure>
    <time_frame>Baseline (Cycle 1 Day 1) and at designated timepoints up to 30 days post last dose. Each cycle is 21 days. (Up to approximately 25 months)</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The EORTC Quality of Life Questionnaire and Lung Cancer Module 13 (QLQ-LC13) is a supplemental lung cancer-specific module used in combination with QLQ-C30. The change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30); Cough (EORTC QLQ-LC13 Item 31); Chest Pain (EORTC QLQ-LC13 Item 40); Dyspnea (EORTC QLQ-C30 Item 8); and Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented. An increase in combined score indicates improvement in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Time to True Deterioration as Assessed by Change from Baseline in Global Health Status/Quality of Life; Cough; Chest Pain; Dyspnea; and Physical Functioning Combined Score</measure>
    <time_frame>Baseline (Cycle 1 Day 1) and at designated timepoints up to 30 days post last dose. Each cycle is 21 days. (Up to approximately 25 months)</time_frame>
    <description>The time to true deterioration will be assessed by change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30); Cough (EORTC QLQ-LC13 Item 31); Chest Pain (EORTC QLQ-LC13 Item 40); Dyspnea (EORTC QLQ-C30 Item 8); and Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score. True deterioration is defined as the first onset of ≥10-point decrease from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">726</enrollment>
  <condition>Nonsquamous Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion Q3W</description>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib</arm_group_label>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV infusion Q3W</description>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib</arm_group_label>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV infusion Q3W</description>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib</arm_group_label>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>IV infusion Q3W</description>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib</arm_group_label>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Oral capsule once daily</description>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib</arm_group_label>
    <other_name>MK-7902</other_name>
    <other_name>E7080</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching lenvatinib</intervention_name>
    <description>Oral capsule once daily</description>
    <arm_group_label>Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of Stage IV (American Joint
             Committee on Cancer [AJCC], nonsquamous NSCLC.

          -  Confirmation that Epidermal Growth Factor Receptor (EGFR), ALK Receptor Tyrosine
             Kinase (ALK), or ROS1 Receptor Tyrosine Kinase (ROS1)-directed therapy is not
             indicated as primary treatment (documentation of absence of tumor-activating EGFR
             mutations AND absence of ALK and ROS1 gene rearrangements OR presence of a Kirsten Rat
             Sarcoma (KRAS) gene mutation).

          -  Have measurable disease based on RECIST 1.1. Note: Lesions that appear measurable, but
             are situated in a previously irradiated area, can be considered measurable (eligible
             for selection as target lesions) if they have shown documented growth since the
             completion of radiation.

          -  Provided an archival tumor tissue sample or newly obtained core or excisional biopsy
             of a tumor lesion (not previously irradiated).

          -  Life expectancy of at least 3 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days
             prior to the first dose of study intervention but before randomization.

          -  Male participants must agree for at least 30 days after the last dose of
             lenvatinib/matching placebo and up to 180 days after the last dose of chemotherapeutic
             agents to:

        Refrain from donating sperm PLUS either:

        Be abstinence from heterosexual intercourse as their preferred and usual lifestyle
        (abstinent on a long term and persistent basis) and agree to remain abstinent OR

        Must agree to use contraception unless confirmed to be azoopsermic (vasectomized or
        secondary to medical cause) as detailed below:

        Agree to use a male condom plus partner use of an additional contraceptive method when
        having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not
        currently pregnant Note: Men with a pregnant or breastfeeding partner must agree to remain
        abstinent from penile-vaginal intercourse or use a male condom during each episode of
        penile-vaginal penetration.

        Note: 30 days after lenvatinib/matching placebo is stopped, if the participant is on
        pembrolizumab only and is greater than 180 days post chemotherapy, no male contraception
        measures are needed.

          -  Female participant is eligible to participate if she is not pregnant or breastfeeding,
             and at least one of the following conditions applies:

        Is not a WOCBP OR Is a WOCBP and using a contraceptive method that is highly effective
        (with a failure rate of &lt;1% per year), with low user dependency, or be abstinent from
        heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term
        and persistent basis), during the intervention period and for at least 120 days post
        pembrolizumab and/or 30 days post-lenvatinib/matching placebo, and up to 180 days post last
        dose of chemotherapeutic agents, whichever occurs last.

          -  Adequate organ function.

          -  Adequately controlled blood pressure (BP) with or without antihypertensive
             medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications
             within 1 week prior to randomization. Note: Participants must not have a history of
             uncontrolled or poorly-controlled hypertension, defined as &gt;150/90 mm Hg for &gt;4 weeks
             despite standard medical management.

        Exclusion Criteria:

          -  Known untreated central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Participants with previously treated brain metastases may participate
             provided they are radiologically stable, clinically stable, and have not required
             steroids for at least 14 days prior to the first dose of study intervention.

          -  History of (noninfectious) pneumonitis that required systemic steroids or current
             pneumonitis/interstitial lung disease.

          -  Radiographic evidence of intratumoral caviations, encasement, or invasion of a major
             blood vessel. Additionally, the degree of proximity to major blood vessels should be
             considered because for exclusion because of the potential risk of severe hemorrhage
             associated with tumor shrinkage/necrosis after lenvatinib-therapy. (In the chest,
             major blood vessels include the main pulmonary artery, the left and right pulmonary
             arteries, the 4 major pulmonary veins, the superior or inferior vena cava, and the
             aorta).

          -  Known history of an additional malignancy, except if the participant has undergone
             potentially curative therapy with no evidence of that disease recurrence for at least
             3 years since initiation of that therapy. Note: The time requirement also does not
             apply to participants who underwent successful definitive resection of basal cell
             carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the
             skin, in situ cervical cancer, or other in situ cancers.

          -  Active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive
             drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed.

          -  Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses
             exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive
             therapy within 7 days prior the first dose of study intervention.

          -  Has had allogeneic tissue/solid organ transplant.

          -  Known history of human immunodeficiency virus (HIV) infection. HIV testing is not
             required unless mandated by the local health authority.

          -  Known history of Hepatitis B. No testing for Hepatitis B or Hepatitis C is required
             unless mandated by the local health authority.

          -  History of a gastrointestinal condition or procedure that in the opinion of the
             investigator may affect oral drug absorption.

          -  Active hemoptysis (at least 0.5 teaspoon of bright red blood) within 2 weeks prior to
             the first dose of study intervention.

          -  Significant cardiovascular impairment within 12 months prior to the first dose of
             study intervention, including history of congestive heart failure greater than New
             York Heart Association (NYHA) Class II, unstable angina, myocardial infarction,
             cerebrovascular accident (CVA)/stroke, or cardiac arrhythmia associated with
             hemodynamic instability.

          -  Known history of active tuberculosis.

          -  Active infection requiring systemic therapy.

          -  Has not recovered adequately from any toxicity and/or complication from major surgery
             prior to the first dose of study intervention.

          -  Previously had a severe hypersensitivity reaction to treatment with a monoclonal
             antibody or has a known sensitivity to any component of lenvatinib or pembrolizumab,
             or as applicable, carboplatin, cisplatin, or pemetrexed.

          -  A WOCBP who has a positive urine pregnancy test within 24 hours prior to randomization
             or treatment allocation. If the urine test is positive or cannot be confirmed as
             negative, a serum pregnancy test will be required.

          -  Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.

          -  Received prior systemic chemotherapy or other targeted or biological antineoplastic
             therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or
             radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was
             completed at least 6 months prior to the diagnosis of metastatic NSCLC.

          -  Received prior treatment with pembrolizumab or any other anti-programmed cell death
             (PD)-1, anti-PD-L1, anti-PD-L2 agent, with lenvatinib or any other receptor tyrosine
             kinase inhibitor (RTKi), or with an agent directed to another stimulatory or
             co-inhibitory T cell receptor.

          -  Received radiotherapy within 14 days prior to the first dose of study intervention or
             received lung radiation therapy of &gt;30 Gy within 6 months prior to the first dose of
             study intervention. Note: Participants must have recovered from all radiation-related
             toxicities to Grade ≤1, not required corticosteroids, and not have had radiation
             pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of
             radiotherapy) to non-CNS disease.

          -  Received systemic steroid therapy (in doses exceeding 10 mg daily of prednisone
             equivalent) within 7 days prior to the first dose of study intervention.

          -  Received a live vaccine within 30 days prior to the first dose of study intervention.

          -  Currently participating and receiving study therapy or has participated in a study of
             an investigational agent and received study therapy or used an investigational device
             within 4 weeks prior to the first dose of study intervention.

          -  History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's
             opinion, is clinically meaningful.

          -  Left ventricular ejection fraction (LVEF) below the institutional (or local
             laboratory) normal range as determined by multigated acquisition scan (MUGA) or
             echocardiogram (ECHO).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>El Camino Hospital Cancer Center ( Site 0529)</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-962-4562</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University ( Site 0519)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-737-2587</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital ( Site 0512)</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>954-267-7748</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Health-Paducah Medical Oncology and Hematology ( Site 0570)</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>270-441-4343</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System ( Site 0563)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-0482</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Lukes Cancer Institute ( Site 0541)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>816-932-2677</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Broome Oncology, LLC ( Site 0562)</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>607-763-8065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Health Roger Maris Cancer Center ( Site 0533)</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>701-234-6161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center ( Site 0504)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>405-271-8001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital Corvallis ( Site 0521)</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>541-768-4950</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital ( Site 0548)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-955-3773</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abington Hospital - Asplundh Cancer Center ( Site 0575)</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-481-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Cancer Center - East Campus ( Site 0544)</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>901683005561236</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkland Health &amp; Hospital System ( Site 0576)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-590-5734</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center ( Site 0558)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-648-1688</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists ( Site 0523)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-281-6864</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University ( Site 0526)</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>304-581-1158</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0367)</name>
      <address>
        <city>Berazategui</city>
        <state>Buenos Aires</state>
        <zip>B1884BBF</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541142262013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Mar del Plata ( Site 0371)</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+542234963224</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEMIC ( Site 0370)</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Autonoma De Buenos Aires</state>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541152990100ext2543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque ( Site 0365)</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DSV</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5493416955611</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Aleman ( Site 0368)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1118AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541148277000 x2955</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Especializado Alexander Fleming ( Site 0369)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5491166936669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEMAIC ( Site 0374)</name>
      <address>
        <city>Cordoba</city>
        <zip>X5008HHW</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5493516212584</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica ( Site 0372)</name>
      <address>
        <city>San Juan</city>
        <zip>J5402DIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+542644211086</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital Western Sydney Local Health District ( Site 0008)</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61288905770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Port Macquarie Base Hospital ( Site 0001)</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61265849805</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris OBrien Lifehouse ( Site 0006)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61285140000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital ( Site 0009)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61288905200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cairns Hospital ( Site 0002)</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61407220229</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital ( Site 0010)</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61731394000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ballarat Health Services ( Site 0003)</name>
      <address>
        <city>Ballarat</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61353204735</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moncton Hospital - Horizon Health Network ( Site 0410)</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5068575669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre ( Site 0407)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9053879495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre ( Site 0414)</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61354966664502</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health ( Site 0406)</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9055768711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sault Area Hospital ( Site 0413)</name>
      <address>
        <city>Sault Ste Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>70575934344402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Cite de la Sante de Laval ( Site 0400)</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4506681010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0412)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>51434535113981</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de la Mauricie et du Centre du Quebec ( Site 0408)</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>819697333363238</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0403)</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4185254444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0380)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4810218</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56957983173</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Catolica del Maule ( Site 0385)</name>
      <address>
        <city>Talca</city>
        <state>Maule</state>
        <zip>3465584</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56981340385</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OrlandiOncologia ( Site 0381)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>7500713</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992214787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez FALP ( Site 0383)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>7500921</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5624205100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile ( Site 0382)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8330032</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56963413803</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradford Hill Centro de Investigaciones Clinicas ( Site 0387)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56229490970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncocentro ( Site 0384)</name>
      <address>
        <city>Vina del Mar</city>
        <state>Valparaiso</state>
        <zip>2520598</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992369820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Antofagasta ( Site 0386)</name>
      <address>
        <city>Antofagasta</city>
        <zip>1240000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56994198125</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital ( Site 0108)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613911339836</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital ( Site 0120)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+861088196479</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital Affiliated to AMU ( Site 0119)</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8615922794329</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital ( Site 0102)</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613905010379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Medical University Nanfang Hospital ( Site 0121)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613632102245</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Harbin Medical University ( Site 0100)</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613624512327</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital ( Site 0112)</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86073188651900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Union hospital Cancer Center ( Site 0123)</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613986252286</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital ( Site 0122)</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613407192282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital ( Site 0115)</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130103</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>43185879120</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University ( Site 0103)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613601783113</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital ( Site 0101)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200443</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+21665550061053</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital ( Site 0111)</name>
      <address>
        <city>Tian Jin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862223340123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110)</name>
      <address>
        <city>Urumuqi</city>
        <state>Xinjiang</state>
        <zip>830000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>13899913829</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Zhejiang University ( Site 0109)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613505719970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital ( Site 0113)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8657188122222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University ( Site 0124)</name>
      <address>
        <city>Wen Zhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613587600968</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss ( Site 0144)</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33388252485</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Nord du Marseille ( Site 0147)</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhone</state>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33491965901</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Foch ( Site 0145)</name>
      <address>
        <city>Suresnes</city>
        <state>Hauts-de-Seine</state>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33146252544</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Cancerologie du Grand Montpellier ( Site 0142)</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33448200904</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Laennec ( Site 0146)</name>
      <address>
        <city>Nantes cedex 1</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33240679993</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Schuman ( Site 0143)</name>
      <address>
        <city>Vantoux</city>
        <state>Moselle</state>
        <zip>57070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33357842937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Cardiologique Louis Pradel ( Site 0141)</name>
      <address>
        <city>Bron</city>
        <state>Rhone-Alpes</state>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33427857700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>L'hopital Nord-Ouest - Centre Hospitalier de Villefranche sur Saone ( Site 0149)</name>
      <address>
        <city>Villefranche sur Saone</city>
        <state>Rhone</state>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33642349915</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin ( Site 0140)</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33158413091</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen GmbH ( Site 0164)</name>
      <address>
        <city>Esslingen</city>
        <state>Baden-Wurttemberg</state>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49711310386510</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest ( Site 0169)</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496976014558</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pius Hospital Oldenburg ( Site 0170)</name>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+494412291610</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen ( Site 0160)</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492418089947</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes ( Site 0165)</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4968411621622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha Maria Halle-Doelau ( Site 0166)</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493455591440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LungenClinic Grosshansdorf GmbH ( Site 0171)</name>
      <address>
        <city>Grosshansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+494412291610</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamato-Onkologie Hamburg Prof. Laack und Partner ( Site 0161)</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4940280065620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center ( Site 0222)</name>
      <address>
        <city>Beer Sheva</city>
        <state>HaDarom</state>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972587040620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center ( Site 0221)</name>
      <address>
        <city>Kfar Saba</city>
        <state>HaMerkaz</state>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97297472414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0224)</name>
      <address>
        <city>Petah Tikva</city>
        <state>HaMerkaz</state>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239378101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shamir Medical Center-Assaf Harofeh ( Site 0227)</name>
      <address>
        <city>Zerifin</city>
        <state>HaMerkaz</state>
        <zip>7030001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>089778003</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0223)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97248542811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center ( Site 0220)</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tell Abib</state>
        <zip>5266202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235307096</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 0225)</name>
      <address>
        <city>Tel Aviv</city>
        <state>Tell Abib</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236973494</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center ( Site 0017)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81529511111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujita Health University Hospital ( Site 0016)</name>
      <address>
        <city>Toyoake</city>
        <state>Aichi</state>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81562932111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 0024)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81471331111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital ( Site 0018)</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81762652000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka Habikino Medical Center ( Site 0020)</name>
      <address>
        <city>Habikino</city>
        <state>Osaka</state>
        <zip>583-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81729572121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital ( Site 0022)</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81728040101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital ( Site 0019)</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81252665111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital ( Site 0026)</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335422511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Komagome Hospital ( Site 0015)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81338232101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR ( Site 0021)</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335200111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital ( Site 0025)</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81734472300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital ( Site 0062)</name>
      <address>
        <city>Cheongju si</city>
        <state>Chungcheongbuk-do [Chungbuk]</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82432696015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center ( Site 0061)</name>
      <address>
        <city>Goyang-si</city>
        <state>Kyonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82319201154</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea St. Vincent s Hospital ( Site 0064)</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Kyonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82312498153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0063)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222280880</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tauranga Hospital ( Site 0004)</name>
      <address>
        <city>Tauranga</city>
        <state>Bay Of Plenty</state>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6475798153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital ( Site 0011)</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6493074949</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 0601)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48501446778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii ( Site 0613)</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48426895551</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0603)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225463066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pleszewskie Centrum Medyczne w Pleszewie Sp. z o.o. ( Site 0615)</name>
      <address>
        <city>Pleszew</city>
        <state>Wielkopolskie</state>
        <zip>63-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>695781830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MED-POLONIA Sp. z o.o. ( Site 0609)</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48505758992</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki im. Mikolaja Kopernika ( Site 0602)</name>
      <address>
        <city>Koszalin</city>
        <state>Zachodniopomorskie</state>
        <zip>75-581</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48502204953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 1 na. NI. Pirogov ( Site 0270)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79031991945</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital with outpatient Clinic ( Site 0262)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79031691379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Radiology Centre ( Site 0260)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79037971178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 0264)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79264375889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omsk Clinical Oncology Dispensary ( Site 0267)</name>
      <address>
        <city>Omsk</city>
        <state>Omskaya Oblast</state>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79139767226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0269)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79111005005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SAHI Republican Clinical Oncological Dispensary of the MoH of RT ( Site 0261)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78435257346</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruna ( Site 0239)</name>
      <address>
        <city>A Coruna</city>
        <state>A Coruna [La Coruna]</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34981178353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau ( Site 0241)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34935565638</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L Hospitalet ( Site 0234)</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932607744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran Canaria ( Site 0244)</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34928441738</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia ( Site 0231)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34963131800437635</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe ( Site 0233)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34663976139</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante ( Site 0240)</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34965933513</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon ( Site 0237)</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915868115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos ( Site 0235)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913303000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0236)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34917277516</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Malaga ( Site 0238)</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+349422033350000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet ( Site 0242)</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34976359268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi ( Site 0314)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+90322338606031</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tıp Fakultesi ( Site 0316)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+9031230543304336</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara Universitesi Tip Fakultesi. ( Site 0317)</name>
      <address>
        <city>Ankara</city>
        <zip>06620</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903125957115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara Sehir Hastanesi ( Site 0323)</name>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0312)</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902124143273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medeniyet Universitesi Tip Fakultesi ( Site 0310)</name>
      <address>
        <city>Istanbul</city>
        <zip>34732</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tıp Fakultesi ( Site 0313)</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323902910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inonu Universitesi Medical Fakultesi ( Site 0318)</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905385003562</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary ( Site 0288)</name>
      <address>
        <city>Aberdeen</city>
        <state>Aberdeen City</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441224553500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Middlesex University Hospital NHS Trust ( Site 0291)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442088872687</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas NHS Foundation Trust ( Site 0280)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442071884251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Georges University Hospitals NHS Foundation Trust. ( Site 0292)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442087253249</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital Campus ( Site 0287)</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441159691169</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospital NHS Trust. St. James University Hospital ( Site 0276)</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441132067598</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary ( Site 0284)</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+447768493428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie NHS Foundation Trust ( Site 0275)</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441619182459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0286)</name>
      <address>
        <city>Wirral</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+447887844080</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trial Information</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>programmed cell death 1 (PD-1, PD1)</keyword>
  <keyword>programmed cell death-ligand 1 (PD-L1, PDL1)</keyword>
  <keyword>programmed cell death-ligand 2 (PD-L2, PDL2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

